The DETOUR 2 Clinical Trial

The Detour Endovascular Technique for Long OcclUsive Fem-pop Revascularization - 2 Clinical Trial

Prospective, single-arm, multi-center, international clinical investigation to evaluate the safety and effectiveness of the PQ Bypass System to access, deliver guidewires, and implant stent grafts for a percutaneous femoropopliteal (fem-pop) bypass.

Study Overview

• Status: Completed
• Conditions: Peripheral Arterial Disease
• Intervention / Treatment: Device: DETOUR System

Detailed Description

The DETOUR2 study is a prospective, single-arm, multi-center, international, non-randomized, safety and effectiveness clinical investigation of the PQ Bypass system.

The PQ Bypass System is intended to improve blood flow in patients with symptomatic peripheral arterial disease due to symptomatic femoropopliteal chronic total occlusions ≥ 20 cm (TASC D) that can include de novo, restenotic, or in-stent restenotic lesions; or Symptomatic femoropopliteal lesions ≥ 24 cm (total lesion length) that can include a chronic total occlusion or a ≥70% lesion that includes de novo, restenotic or in-stent restenosis (complex TASC C), with reference vessel diameters ranging from 5.0 - 6.7 mm, by investigator visual assessment.

• Study Type: Interventional
• Enrollment (Actual): 202
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Germany
  • Arnsberg, Germany, 59759
    • Klinikum Hochsauerland GmbH
  • Frankfurt, Germany
    • Cardioangiologisches Centrum Bethanien
  • Leipzig, Germany, 04203
    • Universität Leipzig
• Latvia
  • Riga, Latvia, 1002
    • Pauls Stradins Clinical University Hospital
• United States
  • Arizona
    • Scottsdale, Arizona, United States, 85251
      • HonorHealth
  • Arkansas
    • Jonesboro, Arkansas, United States, 72401
      • St. Bernard's Medical Center
    • Little Rock, Arkansas, United States, 72211
      • Arkansas Heart Hospital
  • California
    • Burlingame, California, United States, 94010
      • Bay Area Vein and Vascular
    • Monterey, California, United States, 93940
      • Community Hospital of the Monterrey Peninsula
    • Mountain View, California, United States, 94040
      • Advanced Cardiovascular Specialists
  • Colorado
    • Denver, Colorado, United States, 80220
      • Denver VA Medical Center
  • Connecticut
    • Darien, Connecticut, United States, 06820
      • The Vascular Experts
  • Florida
    • Jacksonville, Florida, United States, 32256
      • First Coast Cardiovascular Institute
    • Miami, Florida, United States, 33176
      • Baptist Hospital Miami
  • Illinois
    • Champaign, Illinois, United States, 61822
      • Christie Clinic
    • Elk Grove Village, Illinois, United States, 60007
      • AMITA Health Alexian Brothers Medical Center
    • Springfield, Illinois, United States, 62701
      • Prairie Education And Research Cooperative
  • Maryland
    • Hyattsville, Maryland, United States, 20782
      • MedStar Health Research Institute
  • Massachusetts
    • Boston, Massachusetts, United States, 02114
      • Massachusetts General Hospital
  • Michigan
    • Bay City, Michigan, United States, 48708
      • McLaren Bay Region Hospital
    • Grandville, Michigan, United States, 49418
      • Advanced Cardiac and Vascular Amputation Prevention Centers
    • Petoskey, Michigan, United States, 49770
      • Cardiac & Vascular Research Center of Nothern Michigan
  • Mississippi
    • Tupelo, Mississippi, United States, 38801
      • Cardiology Associates of North Mississippi
  • New Mexico
    • Albuquerque, New Mexico, United States, 87102
      • New Mexico Heart Institute
  • New York
    • New York, New York, United States, 10032
      • New York-Presbyterian / Columbia University Medical Center
  • North Carolina
    • Raleigh, North Carolina, United States, 27607
      • North Caroline Hearth and Vascular- University of North Carolina Rex
  • Ohio
    • Cincinnati, Ohio, United States, 45219
      • The Christ Hospital - The Carl & Edyth Lindner Center for Research & Education
    • Cleveland, Ohio, United States, 44195
      • Cleveland Clinical Foundation
  • Rhode Island
    • Providence, Rhode Island, United States, 02906
      • Miriam Hospital
  • South Carolina
    • Greenville, South Carolina, United States, 29615
      • Greenville Health System
  • Texas
    • Dallas, Texas, United States, 75069
      • North Dallas Research Associates
    • Lubbock, Texas, United States, 79409
      • Texas Tech
  • Virginia
    • Norfolk, Virginia, United States, 23507
      • Sentara Norfolk General Hospital
  • Wisconsin
    • Milwaukee, Wisconsin, United States, 53233
      • Aurora Research Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 90 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

All subjects are required to meet the following inclusion criteria in order to be considered eligible for participation in the study:

General Inclusion Criteria

1. Age > 18 and ≤ 90 years of age.
2. Willing and able to provide informed consent.

3. Subject is willing to undergo all follow-up assessments according to the specified schedule over 36 months.

   Clinical Inclusion Criteria

4. Chronic, symptomatic lower limb ischemia defined as Rutherford clinical categories 3, 4, or 5.
5. Venous Clinical Severity Score < 3.

6. Subject is a suitable candidate for angiography and endovascular intervention and, if required, is eligible for standard surgical repair.

   Angiographic Inclusion Criteria

7. Symptomatic femoropopliteal chronic total occlusions ≥ 20 cm (TASC D) that can include de novo, restenotic, or in-stent restenotic lesions; or Symptomatic femoropopliteal lesions ≥ 24 cm (total lesion length) that can include a chronic total occlusion or a ≥70% lesion that includes de novo, restenotic or in-stent restenosis (complex TASC C), by investigator visual assessment.
8. Reference vessel diameter ≥ 4.5 and ≤ 6.7 mm, by investigator visual assessment.
9. Subject has a patent popliteal artery (<50% stenosis) distal to the landing zone
10. Able to successfully access the SFA origin for entry of the crossing device.
11. At least one patent infrapopliteal vessel (<50% stenosis) with run-off to the ankle or foot.
12. A significant stenosis (≥ 50%) or occlusion of an ipsilateral, inflow artery (e.g. aortoiliac, common femoral) must be successfully treated (use of investigational treatment prohibited) prior to treatment of the target lesion. Successful treatment is defined as no complications and less than 30% residual stenosis following intervention.

General Exclusion Criteria

1. Participating in another investigational clinical study.
2. Anticipated life expectancy less than 1 year or medical comorbid condition(s) that could limit the subject's ability to comply with the requirements of the trial.

3. Subject has other medical, social or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment, and the procedures and evaluations pre- and post-treatment.

   Clinical Exclusion Criteria

4. History of deep vein thrombosis on either limb.
5. Thrombophlebitis, within the previous 30 days.
6. 6. Planned major amputation of the target limb, including minor amputation (above the ankle).
7. Prior distal amputation (above the transmetatarsal) of the target limb.
8. Known or suspected active infection at the time of the procedure (e.g., WIfI foot infection grade 3: Severe infection. Local infection with systemic inflammatory response syndrome [SIRS])
9. Rutherford clinical category 0, 1, 2 or 6.
10. Has acute or chronic renal disease with GFR ≤ 30 ml/min per 1.73 m2 and/or elevated serum creatinine >2.5mg/dL (220µmol/L) or on dialysis.
11. Known hypersensitivity/allergy to the investigational devices and/or required pharmacotherapy that cannot be safely managed.
12. Morbid obesity that does not allow for safe vascular access or imaging.
13. Subject has a known coagulopathy or has bleeding diatheses, thrombocytopenia with platelet count less than 100,000/microliter or INR > 1.8.
14. Requires coronary or peripheral procedure within 30 days prior to or planned within 30 days post treatment of the target lesion.
15. Has a known history of intracranial bleeding or aneurysm, myocardial infarction or stroke within the last 3 months.
16. Subject is pregnant or breast-feeding. Angiographic Exclusion Criteria
17. Stent within 3 cm of SFA ostium.
18. Previous bypass surgery on the target limb.
19. Subject has significant disease or obstruction (≥50%) of the inflow tract that has not been successfully treated at the time of the index procedure (success measured as ≤30% residual stenosis, without complication)
20. Presence of aneurysm or acute thrombus in the target limb.
21. Thrombolysis of the target vessel within 72 hours prior to the index procedure, where complete resolution of the thrombus was not achieved.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Single-Arm; This is a prospective, single-arm, multi-center, international clinical investigation to evaluate the safety and effectiveness of the DETOUR System, delivery guidewires, and implant stent grafts for percutaneous femoropoliteal bypass compared to Performance Goals (PG)

Device: DETOUR System; The DETOUR System is intended to improve blood flow in patients with peripheral arterial disease in symptomatic femoropopliteal lesions due to chronic total occlusions ≥ 20 cm (TASC D) that can include de novo, restenotic, or in-stent restenotic lesions; or total lesion lengths ≥24 cm that can include chronic total occlusions or a ≥70% lesion that includes de novo, restenotic or in-stent restenosis (complex TASC C).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Primary Patency	Primary patency at 12 months as evidenced by a peak systolic velocity ratio (PSVR) ≤2.5 from DUS and no clinically-driven re-intervention within the stented segment.	12 months
Major Adverse Events at 30 Days	Freedom from a Major Adverse Event (MAE) at 30 days post-procedure (defined as any occurrence of the following events: Death, Clinically-Driven Target Lesion Revascularization (CD-TLR), Major Amputation of(above the Treated Limb,ankle), Symptomatic Deep Vein Thrombosis (DVT), Pulmonary Embolism, or procedure-related bleeding requiring any transfusion of packed red blood cells or surgery).	30 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Stent Graft Separation and Migration	Stent graft separation and migration identified via ultrasound imaging	30 Days
Stent Graft Separation and Migration Via 12-Month X-Ray	Stent graft separation and migration identified via X-ray	12 Months
Stent Graft Fracture Via 12-Month X-Ray	Stent graft fracture identified via X-ray	12-Months

Collaborators and Investigators

• Sponsor: Endologix
• Investigators: Principal Investigator: Jihad Mustapha, MD, Advanced Cardiac and Vascular Amputation Prevention Centers; Principal Investigator: Sean Lyden, MD, The Cleveland Clinic

Study record dates

Study Major Dates

• Study Start (Actual): December 13, 2017
• Primary Completion (Actual): December 22, 2021
• Study Completion (Actual): November 13, 2023

Study Registration Dates

• First Submitted: April 11, 2017
• First Submitted That Met QC Criteria: April 17, 2017
• First Posted (Actual): April 18, 2017

Study Record Updates

• Last Update Posted (Actual): April 2, 2025
• Last Update Submitted That Met QC Criteria: March 13, 2025
• Last Verified: March 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Vascular Diseases; Cardiovascular Diseases; Atherosclerosis; Arteriosclerosis; Arterial Occlusive Diseases; Peripheral Arterial Disease; Peripheral Vascular Diseases
• Other Study ID Numbers: STP 203

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes